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ABSTRACT
Objective: Chronic liver diseases (CLDs) impose a
significant socioeconomic burden on patients and the
healthcare system, but to what extent remains
underexplored. We estimated costs and health-related-
quality-of-life (HRQoL) among patients with CLDs at
different stages and with different aetiologies.
Design: A cost-of-illness study was conducted. Direct
costs, productivity loss and HRQoL were estimated in
patients with chronic hepatitis, cirrhosis hepatocellular
carcinoma (HCC) or where orthotopic liver
transplantation (OLT) had been performed, for hepatitis
C virus (HCV) infection, hepatitis B virus (HBV)
infection, or in those with liver disease from other
causes. Patients were retrospectively observed for
6 months. The societal perspective was adopted to
calculate costs.
Results: In total, 1088 valid patients (median
age=59.5 years, 60% men) were enrolled. 61% had
chronic hepatitis, 20% cirrhosis, 8% HCC and 12%
underwent OLT. HCV infection was identified in 52% and
HBV infection in 29% of the patients. Adjusted mean
direct costs increased from <€200/patient-month in HCV-
infected patients with hepatitis to >€3000/patient-month
in HBV infected patients with OLT. Antiviral treatment was
the cost driver in patients with hepatitis, while hospital
costs were the driver in the other subgroups.
Absenteeism increased from HBV-infected patients with
hepatitis (0.7 day/patient-month) to patients with OLT
with other aetiologies (3.7 days/patient-month). HRQoL
was on average more compromised in cirrhosis and
patients with HCC, than in hepatitis and patients with
OLT. HBV-infected patients generated higher direct costs,
patients with other aetiologies generated the highest
productivity loss and HCV-infected patients reported the
worst HRQoL levels.
Conclusions: The present study can be considered a
benchmark for future research and to guide policies
aimed at maximising the cost-effective of the
interventions.
INTRODUCTION
Chronic liver diseases (CLDs) constitute a
major medical and public health problem
worldwide. According to the latest report of
the European Center for Disease Prevention
and Control,1 the prevalence of chronic hepa-
titis B virus (HBV) infection in the general
population ranges from 0.2% to over 7% in
the different European countries, while the
prevalence of hepatitis C virus (HCV) varies
from 0.4% to over 3% in Mediterranean coun-
tries. However, as high-risk and vulnerable
groups such as migrants, homeless persons
and prisoners tend to be under-represented in
general population studies, the HCV and HBV
prevalence data are likely underestimated.
Summary box
What is already known about this subject?
▸ Because of their relatively high prevalence and
clinical consequences, chronic liver diseases
(CLDs) constitute a major medical and public
health problem worldwide.
▸ CLDs also impose a significant socioeconomic
burden on affected individuals and on the
healthcare system.
▸ In the past years, several studies have analysed
implications on the burden of disease such as
direct costs, or loss of productivity, or
health-related-quality-of-life (HRQoL) among
patients with CLDs. However, a comprehensive
picture of the global socioeconomic impact of
the different CLDs was still lacking.
What are the new findings?
▸ This study provides the most complete picture
of the socioeconomic burden attributable to the
different CLD stages caused by hepatitis C virus
(HCV) infection, hepatitis B virus (HBV) infection
or other aetiologies, adopting the societal
perspective.
▸ Direct costs (ie, medical and other related costs)
and loss of productivity increase with the
disease progression from chronic hepatitis to
cirrhosis, to hepatocellular carcinoma (HCC) and
orthotopic liver transplantation (OLT), while
HRQoL decreases from hepatitis to cirrhosis and
HCC, but slightly improves in patients with OLT.
▸ HBV-infected patients generated higher direct
costs, patients with other aetiologies generated
the highest productivity loss and HCV-infected
patients reported the worst HRQoL levels.
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Individuals with chronic hepatitis B and/or C virus infec-
tion remain infectious to others and are at risk of develop-
ing serious liver diseases such as cirrhosis and
hepatocellular cancer (HCC) later in life.2–4 The natural
history and progression of chronic HBV-related and
HCV-related diseases is complex, highly variable and can
involve individuals for most of their life.5 6 However, many
patients who might beneﬁt from treatment still remain
undetected, allowing progression of the disease with
severe consequences in terms of healthcare resource con-
sumption and quality of life.1 Participants at a recent hepa-
titis B and C summit conference7 underlined that
although the threat posed by chronic viral hepatitis is
becoming more apparent in Europe, there is still little
understanding at the public or policy level of the health
and implications of hepatitis B and C, from a healthcare as
well as societal point of view. CLDs also impose a signiﬁ-
cant socioeconomic burden on affected individuals and
on the healthcare system. In recent years, several studies
have been conducted to quantify some implications
regarding the burden of the diseases, such as direct costs,
or loss of productivity or health-related-quality-of-life
(HRQoL) among patients with CLDs. However, most of
the studies were conducted in the Americas or in Asiatic
countries, or focused on HCV infection or sequelae.8–19
A comprehensive picture of the global socioeconomic
impact of the different CLDs is still lacking. Knowledge of
the global socioeconomic burden of this complex phe-
nomenon is paramount for planning adequate screening
and treatment policies aimed at maximising the beneﬁts
and efﬁciency of treatment strategies.
The aim of the present study was to estimate the socio-
economic impact and HRQoL among patients diagnosed
with CLDs at different stages and with different
aetiologies.
PATIENTS AND METHODS
Study design
A retrospective, prevalence-based cost-of-illness (COI)
study, named COME (COsti delle Malattie Epatiche), involv-
ing the enrolment of patients over 1 year, was conducted.
In our study, we estimated medical and non-medical
costs (direct costs), loss of productivity (indirect costs)
and health-related quality of life (intangible costs) in
patients with a conﬁrmed diagnosis of CLDs. To
conduct this study, we adopted the society’s point of
view, that is, the point of view of patients and their
family/caregivers (relatives or friends), and of the third
party payer, which in Italy is the National Health Service.
To collect economic data, we adopted a retrospective
time horizon of 6 months before enrolment, which in
previous similar studies on patients affected by chronic
diseases such as CLDs has been shown to be a reason-
able time period.20
Participants and setting
We sequentially enrolled adult patients with CLDs, for
around 1 year, at the Gastroenterology Unit of two ter-
tiary centres in Italy: Papa Giovanni XXIII Hospital of
Bergamo and Federico II University hospital in Naples.
The recruitment time of 1 year was decided as recog-
nised suitable to be able to recruit all the target patients
who were in care at the participant centres during the
study conduction. To be eligible, patients had to meet
the following criteria: age >18 years, diagnosis of CLD,
and ability to understand the objective and contents of
the study, and to report the information required.
Eligible patients had to sign an informed consent form,
after receiving information, on the aim of the study, the
type of data and the method of data collection. The par-
ticipants were classiﬁed according to the most advanced
condition diagnosed (ie, chronic hepatitis, cirrhosis,
hepatocellular carcinoma) or whether an orthotopic
liver transplantation (OLT) had been performed or not.
Patients classiﬁed as with chronic hepatitis were by deﬁn-
ition without cirrhosis or hepatocelluar carcinoma, and
were patients on active antiviral treatment, or on post-
treatment follow-up (both responder or not), or on
regular surveillance follow-up for CLD. As regards
patients with cirrhosis, the diagnosis of this condition
was either histological or clinical, the latter based on
imaging (US scan, CT scan), biochemical (ie, low plate-
lets level) and/or according to clinical evidence of cir-
rhosis. The patients were also classiﬁed into three
groups according to the earliest aetiological factor
identiﬁed: HCV infection, HBV infection or other
causes, which included viral coinfections, alcoholic
liver disease, cholestatic disease and autoimmune
disease. The study was conducted in agreement with
the National Regulatory Requirements, International
Conference on Harmonization Guidelines for Good
Clinical Practice and the 18th World Medical
Assembly,21 and all subsequent amendments. The study
protocol was accepted by the ethics committees of the
two participating hospitals.
Data collection and costs estimate
The following data were collected at the enrolment of
each patient: sociodemographics and information on
Summary box
How might it impact on clinical practice in the
foreseeable future?
▸ The use of effective interventions such us screening and treat-
ments, implemented from the early stages of liver diseases,
appears necessary to reduce worsening of patient health, and
direct and indirect costs. The availability of new antiviral ther-
apies is expected to change the medical approach towards
patients with CLDs as well as the treatment. A proper knowl-
edge of the global socioeconomic burden of CLDs is para-
mount to plan adequate screening and treatment policies
aimed at maximisation of cost-effectiveness of interventions.
The present study can be considered a benchmark for future
research and to guide policies aimed at maximising the cost-
effective of the interventions.
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habits, on diagnosis and aetiology, on resource con-
sumption for reasons attributable to the liver disease
and on HRQoL. Depending on the type of data,
these were reported by the physicians (eg, data on diag-
nosis and aetiology) or by the patients themselves
(eg, HRQoL, loss of productivity) or by the physicians
after asking the patients about details (eg, on medical
visits or drug treatment). Ad hoc structured question-
naires were prepared and used to collect the data: the
patients were asked to autonomously complete a paper
questionnaire containing the standard version of the
HRQoL questionnaire (see later for details), questions
on loss of productivity and on non-conventional treat-
ment (ie, homeopathic products, herbal drugs, vitamins,
antioxidant or supplement products, alternative techni-
ques/therapies, special diets) used for reasons attribut-
able to their liver condition. The physicians completed
an electronic database in which they input information
gathered from medical records (eg, clinical data) or spe-
ciﬁed by the patients (eg, treatment details).
As regards resource consumption, to estimate direct
medical costs we collected information on conventional
drug treatment and on non-conventional treatment to
treat the liver disease, on hospitalisations, and on out-
patient specialist medical visits and diagnostic tests attrib-
utable to the liver disease. Data on the amount of
non-medical resource consumption attributable to the
liver disease (ie, on travel and/or accommodation to
reach the hospital or medical practice, and on formal
caregiving, such as paid assistance at home) were also
collected.
To convert these data to monetary terms, we multiplied
the amount of resources consumed by their unit cost
derived from tariffs or prices applicable in Italy in 2011. In
particular, medical costs were quantiﬁed using prices/tariffs
paid by the National Health Service: the Italian Drug
Agency price list22 was used for drug costs. Costs of hospital
admissions were calculated according to the diagnosis-
related group regional tariffs.23 Costs for outpatient services
were obtained from the regional outpatient lists.24
The medical services paid by the patients (provided as
private sector care) were quantiﬁed utilising the infor-
mation on the out-of-pocket cost speciﬁed by each
participant.
Also, we collected information on productivity lost by
the patients themselves or by their informal caregivers
(ie, family members or friends) who mainly helped the
patients to manage their condition. The patients were
asked to specify whether, during the previous 6 months,
they had had any quality/efﬁciency reduction in
working, studying or performing any other everyday
activity. They were also asked to report the number of
lost days/hours of productivity, if any, and to specify
whether they had changed or lost their job for reasons
attributable to their hepatic condition in the previous
6 months. Furthermore, we collected data on the
number of days or hours of work the informal caregiver
lost to help the patient with his/her condition.
HRQoL was assessed using the EQ-5D questionnaire,
which is a generic HRQoL instrument for describing
and valuing health,25 very useful to calculate utility for
the obtainment of quality-adjusted life years (QALYs),
which is a useful outcome indicator for pharmacoeco-
nomic evaluations (cost-utility analyses) of treatment
options. With the EQ-5D, the respondents are asked
about their HRQoL on the current day. The tool consists
of two parts: a descriptive system (EQ-5D proﬁle) consist-
ing of ﬁve domains, namely ‘mobility’, ‘self-care’,
‘anxiety/depression’, ‘usual activities’ and ‘pain/discom-
fort’. The standard version of the descriptive system
includes three levels of severity per domain (‘no
problem’, ‘some/moderate problems’, ‘extreme pro-
blems/impossible to do’).
We also used a new version of the EQ-5D descriptive
system, with ﬁve levels of severity for each domain
(EQ-5D-5L): ‘no problem’, ‘mild problems’, ‘moderate
problems’, ‘severe problems’ and ‘extreme problems’,
with the aim of obtaining more precise data from
patients with CLDs. We compared the performance of
the EQ-5D-5L with the standard 3L version in this cat-
egory of participants. Results on this comparison have
been published elsewhere.26 The second part of the
questionnaire consists of a visual analogue scale (EQ-5D
VAS) measuring the overall HRQoL, ranging from 0
(worst imaginable health state) to 100 (best imaginable
health state).
In this paper, we report the HRQoL results obtained
with the VAS and as utility indexes. To calculate the
utility index from the data obtained with the EQ-5D-3L
descriptive system (named 3L utility index), the
Italian-speciﬁc social tariffs were used,27 while the data
collected with the EQ-5D-5L descriptive system were con-
verted into utilities (named 5L utility index) using the
mapping algorithm developed by van Hout et al28 and
applied on the Italian social tariffs.
Data analyses
Sociodemographic and clinical characteristics of the
study sample, and resource consumption for all categor-
ies, are described with proportions for categorical data,
mean as the central tendency parameter for continuous
data, and minimum and maximum values as dispersion
parameters.
In particular, consumption of resources related with
direct costs is expressed as the frequency of patients
consuming each item, or the frequency of cost items
(eg, hospital accesses, outpatient claims) occurring
in the different subgroups of patients. Costs for each category
were then quantiﬁed in monetary terms and expressed as
mean (minimum–maximum) €/patient-month.
Loss of productivity results are reported as the propor-
tion of patients with reduced efﬁciency and/or who lost
days or hours of work/study/everyday activities. These
are also expressed in terms of mean (minimum–
maximum) days/patient-month of productivity loss.
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HRQoL is reported as mean of the VAS score and
mean of the utility indexes estimated from the
EQ-5D-3L, and from the EQ-5D-5L.
Direct costs, loss of productivity and HRQoL can be
inﬂuenced by the patients’ characteristics or events;
while some characteristics or events are directly related
with the target condition or its management, for
example, disease stage, aetiology, treatment, surgery,
other aspects such as age, gender, education, working
status, etc, can be related with costs and/or HRQoL
regardless of liver condition, as ‘confounders’. We aimed
to estimate costs and HRQoL in each stage of the CLDs
and according to each aetiology, adjusting the estimates
for the other aspects that could be related with costs or
HRQoL as confounders. Accordingly, we conducted
multivariable regression models in which the dependent
variables, that is, the variables that we aimed to estimate,
were total direct costs, loss of days of productivity or VAS
or utility index scores for HRQoL. As independent
(explanatory) variables, the models included the disease
condition and aetiology in order to obtain estimates spe-
ciﬁc for each subcategory of patients, plus those vari-
ables that were considered potential confounders and
for which we aimed to adjust for. The choice of these
confounding variables was made according to knowl-
edge from past experience in the areas of CLDs and of
health economics, from the literature that was available
at the time of this study conduction, and according to
the performance of the statistical models.
In particular, we adopted the general linear models
(GLM) to estimate direct and indirect mean costs,
because these variables present a highly skewed distribu-
tion (instead of a Gaussian distribution), that is, few par-
ticipants generate very high costs, while most generate
low costs. Furthermore, costs cannot be of a negative
sign, hence the lowest possible value corresponds to 0,
and can theoretically be of an inﬁnite amount. Family
and link functions of the GLM model were chosen by
the Modiﬁed Park Test for the former and by the
Pearson Correlation and the Pregibon Link tests for the
latter, resulting in a model with γ family and root square
link functions. With these models, direct costs and loss
of days of productivity (dependent variables) were esti-
mated as mean €/patient-month and mean days lost
from everyday activities/patient-month, respectively. The
independent variables included in these models were:
disease stage and aetiology to obtain estimates in each
speciﬁed subgroup, while age, gender, working status,
marital status, time from diagnosis, occurrence of exami-
nations for evaluation of liver transplantation, and
current and type of therapy were added as possible
confounders.
To estimate the mean VAS score and utility indexes,
we applied the linear regression models using the
Ordinary Least Square method. The following inde-
pendent variables were included: disease condition and
aetiology to obtain estimates in each subgroup speciﬁed,
while age, gender, education, working status, marital
status, alcohol use, time from diagnosis, and current and
type of therapy were added to adjust for these possible
confounders.
Regression coefﬁcient estimates, z (GLM), t (OLS)
and p values are reported for each model.
As regards the management of missing data: if missing
data from one item were few and did not interfere with
the analyses, they were ignored, otherwise, they were
ﬁlled using means or most frequent value calculated
from the available data of the same variable. If missing
data of an item were many, the related variable was not
included in the analyses. If missing data from one par-
ticipant were many, all the data from that participant
were not included in the analyses.
All analyses were performed using SPSS V.15.0 soft-
ware (SPSS, Chicago, Illinois, USA) and with STATAV.11
version (StataCorp LP, USA).
RESULTS
Sample description
From January 2010 to December 2011, data from 1091
consecutive patients were collected. The data of three
patients were excluded from the analyses because two
patients withdrew their informed consent after complet-
ing the questionnaire, and too few data were available
from one patient. Hence, the study sample involved
1088 patients aged 18–89 years, 60% men. Description
of the study sample is reported in table 1. As regards
patients belonging to the OLT subgroup, 12 (9.3% of
the transplanted patients) underwent OLT within the
6 months prior to enrolment.
Medical resources consumption
Treatment
During the observational period, 35.6% of the patients
did not receive any treatment for their hepatic condi-
tion, 34.7% received only conventional drug treatment,
18.9% underwent conventional and unconventional
treatments, and 10.7% underwent unconventional treat-
ment alone. In particular, antiviral drug treatment was
taken by 24% of the full study sample. Table 2 shows the
proportion of patients taking antiviral treatment strati-
ﬁed according to their condition and aetiology.
Patients reporting having received unconventional
treatment during the observational period (35.8% in
total) more frequently took vitamins, antioxidant or sup-
plement products (59.4% of patients using unconven-
tional treatment) and special dietary products (37.5%),
while up to 33.7% took homoeopathy and/or herbal
medicines and/or used alternative techniques/
therapies.
Hospitalisations and outpatient accesses
Overall, 34.7% of patients were hospitalised one or more
times as day-hospital and/or ordinary regimen admis-
sion during the observational period: 19.6% of the
patients who were hospitalised had hepatitis (81% of
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those admitted as day-hospital regimen, 21% admitted
in ordinary regimen), 28.3% had cirrhosis (73.1% of
those admitted as day-hospital, 45% admitted in ordin-
ary regimen), 18% had HCC (77.1% of those admitted
as day-hospital, 45.7% admitted in ordinary regimen)
and 34.1% had undergone OLT (100% of those admit-
ted as day-hospital and 34% admitted also in ordinary
regimen).
The overall number of hospitalisations during the
observational period was around 1400, with 86% occur-
ring as day-hospital regimen. Overall, an average of 1.4
accesses per patient-month occurred: 1.3 among patients
with hepatitis, 1.5 among those with cirrhosis, 1.6 among
patients with HCC and 2.6 accesses per patient-month
among patients with OLT. The most frequent hospital
accesses occurred for post-OLT follow-up (36.5% of all
hospital accesses) or OLT evaluation (25.8%).The
patients were mainly hospitalised for diagnostic reasons,
representing 94% of hospital accesses in hepatitis and
transplanted patients, and 82–83% in those with cirrho-
sis or HCC. The other hospital accesses occurred for
therapeutic reasons.
Outpatient accesses occurred in 85.6% of the study
sample. In particular, 20.8% of patients with at least one
outpatient access had hepatitis, 28.2% had cirrhosis,
18.2% had HCC and 32.7% were patients with OLT.
Around 4200 outpatient accesses occurred in total, cor-
responding to a mean of 0.6 accesses per patient-month,
98% of which were due to specialist medical visits or
laboratory/instrumental tests.
Direct costs
From the crude estimates we found that the mean total
direct costs increase from hepatitis to the more
advanced conditions (table 3). However, some cost items
contributed differently to the total direct costs between
the different disease conditions: while the cost of con-
ventional treatment was on average the driver among
patients with hepatitis, followed by hospitalisations, this
cost item generated the highest mean costs, and conven-
tional drug treatments generated the second most
important cost item in patients with cirrhosis, HCC and
OLT. In the OLT subgroup, which generated the highest
hospital mean costs, 40.2% of the inpatient costs were
attributable to the 12 patients who underwent liver trans-
plantation within the 6 months before enrolment.
As regards conventional treatment, in patients with
hepatitis, costs were 97.6% attributable to antiviral treat-
ment, whereas in HCC and patients with OLT, antiviral
treatment contributed to 45% and 14% of treatment
costs, respectively.
If we focus on patients who received antiviral treat-
ment, those with HBV infection cost €471.9/patient-
month in patients with hepatitis, €380.9/patient-month
in the cirrhosis subgroup, €374.9/patient-month in the
HCC subgroup and €176.3/patient-month in the OLT
subgroup.
Meanwhile, among patients with HCV infection receiv-
ing antiviral treatment, it cost €1269.2/patient-month in
those with hepatitis, €463.8/patient-month in cirrhotic
patients, €433.2/month in the only HCC patient receiv-
ing antiviral treatment and €768.4/patient-month in the
patients with OLT.
As regards the other direct costs, non-medical costs
were the third (cirrhosis, HCC and OLT) or fourth most
important cost item, while unconventional treatment
(hepatitis, cirrhosis and HCC) and outpatient (OLT)
costs were the least expensive items.
From the regression model (table 4) we found a statis-
tically signiﬁcant (p<0.01) increase of the mean total
direct costs in cirrhosis, HCC and patients with OLT
compared with patients with hepatitis. In contrast, the
differences between the aetiological subgroups were not
statistically signiﬁcant (p>0.1). Other variables that were
found to be signiﬁcantly related with total direct costs
were the occurrence of evaluation for liver transplant-
ation (p<0.001), and if the patients were following a
drug therapy (p<0.01). Figure 1A shows the trends of
the mean total costs estimated in each group of patients
deﬁned for diagnosis and aetiology, adjusted for the pos-
sible confounders included in the regression model.
Loss of productivity
Almost half (44.7%) of the participants reported that
they had less efﬁciency and/or more lost time in doing
their everyday activities during the previous 6 months.
Twenty patients also speciﬁed that they lost their job for
reasons attributable to their condition: seven patients
with hepatitis, six with cirrhosis, one with HCC and six
Table 2 Patients who took antiviral treatment, stratified by aetiology and disease condition
Aetiology
Hepatitis
N (%*)
Cirrhosis
N (%*)
HCC
N (%*)
OLT
N (%*)
Total by aetiology
N (%*)
HCV 42 (12.1) 3 (2.6) 1 (1.9) 16 (2.8) 62 (11.0)
HBV 111 (50.2) 21 (50.0) 10 (83.3) 37 (100) 177 (56.7)
OTHER causes† 3 (3.5) 3 (5.1) 3 (17.6) 11 (25.6) 20 (9.8)
Total by disease condition 156 (23.9) 27 (12.5) 14 (17.1) 64 (49.6) 259 (24.0)
*Percentages are calculated using as denominator the number of patients belonging to each subgroup by aetiology within each subgroup by
disease condition (see table 1).
†Other causes included alcoholic liver disease, cholestatic disease and autoimmune disease.
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation.
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who underwent OLT. As regards the time lost from
everyday activities, an average of 0.7 days/patient-month
were lost by the patients overall. Moreover, 44.8%
patients declared they received help from informal care-
givers, with an estimate of a further 0.3 days/patient-
month of caregivers’ productivity lost, across the full
study sample.
From the regression model (ﬁgure 1B) we found an
increase of the mean loss of productivity in cirrhosis
(not signiﬁcant, p>0.200), HCC and in patients with
OLT (p<0.05) compared with patients with hepatitis. In
contrast, the differences between the different aetio-
logical subgroups were not statistically signiﬁcant
(p>0.1). Other variables that were found to be signiﬁ-
cantly related with the loss of productivity were the
occurrence of drug therapy (p<0.05) and HRQoL mea-
sured with the VAS. Figure 1A shows the trends of the
adjusted mean loss of productivity estimated in each
group of patients deﬁned for diagnosis and aetiology.
Health-related quality of life
The model results for the VAS score, the 3L and the 5L
utility indexes, are detailed in table 4. Considering the
other variables included in the model equal, patients
with cirrhosis had lower levels than patients with hepa-
titis, those with HCC had lower levels than patients with
cirrhosis, while in patients with OLT, HRQoL levels
almost reached, on average, the same levels as those of
patients with hepatitis. However, these differences were
generally not statistically signiﬁcant. As regards aetiology,
HCV patients had lower levels than HBV patients and
patients with other causes, making these differences gen-
erally statistically signiﬁcant. Figures 1C, 1D and 1E show
the estimates for each category of interest and have
been adjusted for all potential confounding variables
included in the models. As regards the VAS (ﬁgure 1C),
the adjusted mean values decrease from hepatitis to cir-
rhosis and HCC, ﬁnally they increase again in patients
with OLT, almost reaching the scores estimated for
patients with hepatitis. Patients with HCV reported the
worst mean levels of HRQoL, followed by patients with
other aetiologies and then by patients with HBV infec-
tion. This trend is somewhat similar to those found for
the 3L (ﬁgure 1D) and the 5L (ﬁgure 1E) utility scores.
DISCUSSION
To the best of our knowledge, this study provides the
most complete picture of the socioeconomic burden
attributable to the different CLDs caused by HCV infec-
tion, HBV infection or other aetiologies, from the soci-
etal perspective, that is, considering the point of view of
the third party payers, the patients and the patients’
family/caregivers.
Direct costs had an increasing trend from patients with
hepatitis (less than €400/patient-month) to those with
cirrhosis (up to €700/patient-month), HCC (up to
€2600/patient-month) and OLT (up to €3000/patient-
month), with some differences detected within the three
aetiological subgroups: within the same disease condi-
tions, patients with HBV infection generated on average
the highest direct costs, followed by patients with other
aetiologies and then by those with HCV infection. In par-
ticular, antiviral treatment was the cost driver in patients
with hepatitis, while hospitalisations generated the
highest mean costs in the other conditions. As regards
patients receiving antiviral drug treatment during the
observational period, patients with hepatitis generated
the highest mean costs, corresponding to €500/patient-
month among hepatitis B patients taking antivirals, and
€1300/patient-month among hepatitis C patients.
Table 3 Direct costs (€/patient/month)
Cost category
Disease condition
Hepatitis Cirrhosis HCC OLT
Mean (minimum–
maximum)
Mean (minimum–
maximum)
Mean (minimum–
maximum)
Mean (minimum–
maximum)
Medical costs
Conventional, antiviral drug
treatment
167.1 (0–1921.9) 47.9 (0–597.2) 62.8 (0–508.8) 150.6 (0–1830.0)
Conventional, other
(non-antiviral) drug
treatment
4.0 (0–325.5) 99.1 (0–1543.5) 75.1 (0–1038.6) 917.9 (25.2–6052.0)
Unconventional treatment 10.2 (0–533.3) 22.5 (0–400.0) 17.3 (0–207.7) 16.8 (0–300.0)
Hospitalisations 49.0 (0–3075.0) 259.3 (0–4612.5) 999.8 (0–2590.3) 1483.9 (38.0–13 370.3)
Outpatient visits/
examinations
16.9 (0–163.2) 25.5 (0–105.0) 23.6 (0–141.3) 8.2 (0–38.7)
Non-medical costs
Formal caregiving 2.7 (0–500.0) 9.2 (0–500.0) 9.3 (0–166.7) 17.8 (0–300.0)
Travelling and
accommodation
12.8 (0–500.0) 38.3 (0–500.0) 41.2 (0–375.0) 79.5 (0–1166.7)
Total direct costs 262.8 (3.7–3166.8) 501.7 (7.9–4693.6) 1229.2 (11.4–3916.0) 2674.7 (155.7–15 669.7)
HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation.
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As regards productivity loss, almost half of the patients
declared reduced ability to work or to do other everyday
activities in the previous 6-month period, and 20 even
lost their job due to their hepatic disease. Absenteeism,
similarly to direct costs, increased from patients with
hepatitis (with an average of around 1 day/patient-
month of absenteeism) to patients with OLT, with up to
almost 4 days/patient-month of absenteeism. However, a
different trend was found between the aetiological sub-
groups: mean days lost were lowest among patients with
HBV infection, higher among those with HCV infection
and followed by those with other aetiologies.
As regards HRQoL, the adjusted score estimates of the
VAS and utility indexes presented a sort of U shape
between the different disease conditions, corresponding
to relatively higher mean levels of HRQoL among hepa-
titis and patients with OLT, and lower levels among cir-
rhosis and patients with HCC, using all the scores VAS,
3L utility and 5L utility. Generally, patients with HCV
reported the worst mean levels of HRQoL, followed by
patients with other aetiologies and then by patients with
HBV infection. Several studies have been conducted in
the past years to assess HRQoL in the different liver dis-
eases and sequelae. However, most of the studies
focused on the diseases caused by HCV infection: the
authors of a systematic review published in 2008 on the
health-state utilities in liver disease29 were able to esti-
mate pooled mean values only for hepatitis C disease
conditions, because all other liver conditions did not
have enough estimates to conduct a meta-analyses. From
this review, the estimates obtained with the EQ-5D,
which was found by the authors as the most frequently
used HRQoL tool, were 0.75 for moderate hepatitis C
and compensated cirrhosis, 0.67 for decompensated cir-
rhosis and 0.71 for OLT. These estimates are lower than
ours (0.90, 0.82, 0.80 and 0.83 in chronic hepatitis, cir-
rhosis, HCC and patients with OLT, respectively), which
can depend on a number of reasons, for example, the
different methods and different study samples adopted
in the different studies, and the different levels of the
social tariffs used to obtain utilities: as regards the
Italian social tariffs used to obtain utilities in the present
study, we found them systematically higher than the
widely used UK tariffs.27 However, the “U shape” trend
of HRQoL levels found in our estimates is conﬁrmed in
a systematic review29 and in original research that was
published in 2008,8 reporting the results of utilities esti-
mated from a sample of patients in Singapore with HBV
infection diseases at different stages. The authors of this
study have speciﬁed that while HBV-infected patients
reported a not very compromised HRQoL at early
stages, from previous literature they found that among
hepatitis C patients, HRQoL is compromised even in
those without advanced liver disease. In our study, the
lowest mean levels of VAS and utilities were estimated in
patients with HCV infection at every disease stage, com-
pared with HBV-infected patients. Also, a direct com-
parison is available with patients affected from other
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causes. Hence, while in their recent review on HRQoL
in people with advanced CLDs30 the authors underline
the controversial results provided by the different studies
likely attributable to the different methods applied, with
the COME study, we are able to make direct compari-
sons of HRQoL between the different disease stages and
the different aetiological factors.
A limitation that could be ascribed to this study is that
it was conducted in two gastroenterology tertiary
centres, where it could be expected that only more
severe patients are treated and were involved in the
COME study. The centres involved in the study manage
CLDs starting from early stages until the very complex
post-transplant stages. Therefore, we do not believe that
the study sample involved in this study could have gener-
ated biased estimates.
A second limitation is that while we report the results
on the ‘other causes’ category of patients, we do not
specify any details according to these patients’ speciﬁc
clinical condition: the low number of patients belonging
to each subcategory would not be suitable to obtain reli-
able and useful estimates. In any case, our estimates
remain useful to identify the burden of CLDs in this cat-
egory of participants, who show high levels of costs and
compromised HRQoL, and could stimulate questions
and hypotheses to investigate on future ad hoc research.
A third potential limitation of this study is that it was
conducted only in Italy, thus potentially limiting the
external validity of our results, as different cost items
and/or different unit costs are generally applicable in
the different healthcare systems, with possibly different
results. Owing to these differences in the healthcare
systems, carrying out accurate and precise international
COI studies in the different healthcare areas is generally
very difﬁcult. Hence, a compromise must be reached to
conduct a methodologically correct and informative
Figure 1 Direct costs as mean €/patient-month (A), absenteeism as mean days/patient-month (B), mean EQ-5D VAS (visual
analogue scale) (C), mean EQ-5D-3L utility (D) and mean EQ-5D-5L utility (E) estimated for each disease condition and
aetiology, and adjusted for possible confounders. For each parameter, the bars show the trends grouped to distinguish between
hepatitis, cirrhosis, hepatocellular carcinoma (HCC) and orthotopic liver transplantation (OLT) patients (groups of three bars per
condition), and aetiologies (black bars for hepatitis C virus (HCV) infection, dark grey bars for hepatitis B virus (HBV) infection,
light grey bars for other causes).
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scientiﬁc work. A study has recently been conducted in
ﬁve European countries to assess costs and HRQoL from
the patients’ perspective.10 However, some drawbacks
were admitted to in that study: because a consumer
panel was used to recruit the patients, it was not possible
to conﬁrm the target diagnosis among the participants;
furthermore, the costs attributable to the condition were
not estimated directly, but derived from a comparison of
costs with a sample of controls. Finally, the study focused
only on HCV infection. In contrast, by conducting our
Figure 1 Continued
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study through gastroenterology hospitals, we involved
patients with a conﬁrmed diagnosis of the different
CLDs. Information necessary to conduct the analyses
was supervised or reported by the doctor and data on
direct cost and productivity loss referred speciﬁcally to
the hepatic condition. Finally, we adopted the perspec-
tive of the healthcare system and the perspective of
patients and their families. Therefore, while on one
hand the study by Vietri et al10 was conducted in several
European countries, on the other, our Italian study can
be considered more complete as regards the greater
number of hepatic conditions considered and the more
complete estimates obtained. Hence, until an inter-
national COI study able to provide complete and precise
estimates on the burden of CLDs is available, the results
of the present study can be considered the most com-
plete available and generally applicable also in other
countries with a similar gross domestic product.
Furthermore, it can give some insights on the approach
and methods that can be applied or adapted in other
healthcare systems for the conducting of similar studies
in other countries.
CLDs affect participants for many years, making
observation of the natural history of these conditions
very difﬁcult, or even impossible. Despite this being a
retrospective and prevalence-based study, that is, not
able per se to prospectively follow patients from the
onset of their conditions, the involvement of a rela-
tively large and heterogeneous study sample covering
all main liver conditions from different aetiologies
allowed us to build a picture of this complex phenom-
enon from many different aspects. This study provides
useful information to plan a strategy for the health-
care system in order to decide the best investment.
These results are even more important in the light of
new antivirals, as they provide information that can be
used to conduct accurate pharmacoeconomic analyses
aimed at understanding the cost-effectiveness of the
new interventions.
A further novelty of this study is that it also provides
utility values obtained using the Italian speciﬁc social
tariffs, the standard and widely used EQ-5D-3L,8 29 and
the recently introduced EQ-5D-5L descriptive system
which will probably be used frequently in future
research, in pharmacoeconomic evaluations and in
decision-making.31–33 Notice that the utility estimates
shown in this paper are different from those presented
in the paper by Scalone et al,26 because at the time of
the publication of that paper, the Italian social tariffs27
were not yet available. Hence, the utility indexes
reported in this paper are to be considered more accur-
ate than those published previously.
To conclude, CLDs compromise patients’ well-being
and generate high costs for the healthcare system and
the society as a whole. Costs increase and HRQoL
worsens with disease progression. The use of effective
treatments in the early stages of liver diseases appears
necessary when aiming at reducing worsening of
patient health, and direct and indirect costs. The
non-availability of effective aetiological treatments for
the most frequent liver dysfunctions (HBV and HCV)
has limited the effectiveness of interventions aimed at
preventing the evolution of such diseases. The avail-
ability of new antiviral therapies for both these virus-
related liver diseases is expected to change the
medical approach towards patients and their treat-
ment. A proper knowledge of the global socio-
economic burden of CLDs is paramount to plan
adequate screening and treatment policies aimed at
maximisation cost-effectiveness of interventions.
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